Mediators of Inflammation / 2013 / Article / Tab 1

Clinical Study

Human Leukocyte Antigen Class II Alleles (DQB1 and DRB1) as Predictors for Response to Interferon Therapy in HCV Genotype 4

Table 1

Baseline clinical, virological, and histological features of sixty-two HCV patients and comparison of these features between responder and nonresponder patients to treatment.

CharacteristicsHCV patients Responders Nonresponders P value
(66.1%) (33.9%)

Male/female51/1134/717/41.000
Age (mean ± S.E)40.53 ± 1.1739.44 ± 1.542.67 ± 1.670.160
Liver function
 ALT (IU/L)
  (mean ± S.E)73.9 ± 4.567.93 ± 585.62 ± 80.041 #
 AST (IU/L)
  (mean ± S.E)61.6 ± 4.961.44 ± 7.1361.9 ± 4.50.956
 AFP (U/L)
  (mean ± S.E)7.1 ± 1.56.7 ± 2.17.78 ± 1.60.692
HCV-RNA level
 Low20 (32.3%)12 (29.3%)8 (38.1%)0.035 #
 Moderate27 (43.5%)21 (51.2%)6 (28.6%)
 High5 (8.1%)2 (4.9%)3 (14.3%)
 Unknown10 (16.1%)6 (14.6%)6 (28.6%)
Activity score
 A149 (79%)35 (85.4%)14 (66.7%)0.044 #
 A213 (21%)6 (14.6%)7 (33.3%)
Fibrosis score
 F128 (45.2%)21 (51.2%)7 (33.3%)0.05 #
 F220 (32.3%)14 (34.1%)6 (28.6%)
 F314 (22.6%)6 (14.6%)8 (38.1%)

Significant difference at P ≤ 0.05; between responder and nonresponder patients to treatment. No patients had A0 or A3 activity and F0 or F4 fibrosis.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.